The role of FAS polymorphisms in prostate cancer has not been studied. Using the PCR-based restriction fragment-length polymorphism methodology, we evaluated FAS gene locus À670 genotypes in DNA from 904 men: 657 prostate cancer patients and 247 healthy controls. We found that carriers of AG or GG genotypes have a statistically significant protection (odds ratio (OR) ¼ 0.30; confidence interval (CI): 0.20-0.44 and OR ¼ 0.22; CI: 0.12-0.74, respectively) for disease with extra-capsular invasion. Taken together, a 72% protection was found for G allele carriers (OR ¼ 0.28; CI: 0.19-0.41). Fas exist as membrane-bound and soluble forms and with opposite roles. They derive from the same gene by alternative splicing. Membrane Fas receptors trigger apoptosis whereas, on the other hand, soluble Fas (sFas) bind to Fas ligand antagonizing Fas-Fas ligand apoptotic pathway. Our results suggest that G allele may reduce sFas levels preventing the apoptotic inhibition caused by the soluble form.
Introduction
Apoptosis is important in the development of organisms and to eliminate unwanted or potentially dangerous cells. Abnormal regulation of apoptosis is implicated in development of certain diseases such as cancer. The acquired ability to resist apoptotic stimuli is one of the primary characteristics of a malignant cell, and alterations in the components of apoptotic pathways is a key mechanism in the development of cancer. 1, 2 The FAS/FASL system is one of the major pathways in apoptosis and is important to regulate cell proliferation and tumor-cell growth. FAS (also known as TNFSF6, CD95 or APO-1) is a cell-surface receptor which interacts with its natural ligand FASL (also known as CD95L), both members of the tumor necrosis factor (TNF) superfamily, to initiate the death signal cascade, which results in apoptotic cell death. [3] [4] [5] [6] Decreased expression of FAS and/or increased expression of FASL favor malignant progression by reducing the tumor-cell apoptosis or by induction of immune-cell apoptosis. 7, 8 In addition, polymorphisms in the FAS gene and perhaps also in the FASL gene that impair apoptotic signal transduction are associated with a high risk of cancer in various models. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Thus, the FAS/FASL system appears to have a role in the development and progression of cancer.
Several single-nucleotide polymorphisms have been identified in the promoter region of the FAS gene, one of them the substitution of A to G at position À670 (FAS À670A/G). 23, 24 This functional polymorphism abolishes the binding site of nuclear transcription element GAS 23 and decreases the binding ability to a GAS-binding protein, STAT1, thus diminishes the promoter activity and decreases the FAS-gene expression. 24 Prostate cancer is the most commonly diagnosed cancer in Western men, and its incidence is rising rapidly in most countries. 25 There is still limited data published on the mechanisms of carcinogenesis of prostate cancer. [26] [27] [28] It has been suggested that genetic polymorphisms may influence the individual's susceptibility to prostate cancer, and that influence is dependent on the population we are studying. [29] [30] [31] [32] [33] [34] [35] [36] Furthermore, the genetic background may alter the natural history of prostate cancer development. [37] [38] [39] Moreover, impaired ability to undergo apoptosis seems to be important in prostate cancer. 40 Polymorphisms in the promoter region of the FAS and FASL genes alter the transcriptional activity of these genes, this could be an important role in Fas/FasL pathway. There are no studies regarding any of these genes in prostate cancer. We hypothesized that FAS functional polymorphisms might have an impact on the development of prostate cancer.
Materials and methods
FAS À670 A/G polymorphism was evaluated in DNA samples from 904 male individuals. From this, 657 were consecutive prostate cancer patients of Portuguese Oncology Institute (Porto). The control group was 247 healthy donors from the northern region of Portugal, with no evidence of prostatic disease, as described previously. 34 All samples were obtained with the informed consent of the participants before their inclusion in the study. Blood samples were collected in tubes containing EDTA. Genomic DNA was extracted from peripheral blood leukocytes by a standard salting-out method according to previously reported protocol. 34 A total of 607 prostate cancer cases were considered with complete data for statistical analysis, from which 370 cases had localized prostate disease and 237 cases had advanced disease (invasion and extension beyond the capsule and/or to the adjacent tissue, or involving regional lymph nodes or distant metastatic sites). The median age for cases was 67 years and for controls 39 years. Clinical characteristics including Gleason grade, tumor stage and age at diagnosis were obtained from medical records.
The FAS polymorphism analysis was carried out using polymerase chain reaction-based restriction fragmentlength polymorphism (PCR-RFLP) technique as described previously. 34 The primers used in the amplification were: FAS-F (forward): 5 0 -ATA GCT GGG GCT ATG CGA TT-3 0 and FAS-R (reverse): 5 0 -CAT TTG ACT GGG CTG TCC AT-3 0 (Metabion, Martinsried, Deutschland). PCR reaction mixture was prepared as follows: 100 ng of genomic DNA was added to 0.5 mM of each primer, 0.2 mM of each deoxyribonucleotide triphosphate (dNTP), 2.0 mM MgCl 2 , Â 1 Taq buffer and 1 U of Taq DNA polymerase (Bioron, Ludwigshafen, Deutschland) to a final volume of 50 ml. The amplification conditions were 951C during 5 min for the initial denaturation step, followed by 35 cycles of denaturation at 941C (1 min), annealing at 551C (45 s) and extension at 721C (1 min). The final extension step consisted of 5 min at 721C. As a negative control, PCR mix without DNA sample was used to ensure the contamination-free PCR product.
Reaction products (15 ml) were digested with 1 U of Bme1390I restriction endonuclease (Fermentas, Vilnius, Lithuania) during 4 h at 371C. After digestion the product was visualized in 3% agarose gel stained with ethidium bromide. An uncut band of 193 bp corresponded to the wild-type homozygous À670 AA genotype, the 136 and 57 bp fragments indicated the polymorphic homozygous À670 GG genotype. The three fragments (193, 136 and 57 bp) indicated the heterozygous À670 AG genotype ( Figure 1 ). Analysis of genotypes was independently carried out by two of the authors (LL and RM). A second PCR-RFLP analysis was carried out in 10% of all samples to confirm the genotype.
Statistical analysis
Data analysis was carried out using the computer software Statistical Package for Social Sciences-SPSS for Windows (version 11.5) and Epi Info (version 6.04a). Statistical differences between mean values of groups were evaluated by using the unpaired Student's t-test or the analysis of variance test. The cases were analyzed according to age at diagnosis, serum prostate-specific antigen (PSA) level, Gleason grade and disease status (advanced vs localized). Odds ratio (OR) and 95% confidence interval (CI) were calculated as a measure of association between FAS genotypes and prostate cancer risk. The Hardy -Weinberg equilibrium was tested by a w 2 -test to compare the observed vs the expected genotype frequencies.
Results
The expected genotype distributions for FAS À670 A/G under Hardy -Weinberg equilibrium were derived for both patients and controls, and they were compared with the observed distributions. This strategy confirmed that the observed distributions were consistent with the Hardy -Weinberg equilibrium (P40.05).
The frequencies of FAS À670 A/G polymorphism in prostate cases and controls are shown in Table 1 . The most common genotype was À670 AG both in cases (57.8%) and controls (54.6%). No statistically significant differences were found between genotype frequencies in prostate cancer patients and healthy individuals.
The patients' main characteristics according to FAS À670 A/G genotypes are summarized in Table 2 . No statistically significant differences were found between FAS À670 A/G genotypes and age (P ¼ 0.423), PSA (P ¼ 0.113) except for Gleason grade (P ¼ 0.042).
In Table 3 , we present genotype and allelic frequencies for FAS À670 A/G polymorphism and the risk for advanced disease in prostate cancer patients. We Table 4 presents the comparison of our results for FAS À670 A/G genotype frequencies with reported frequencies for other populations, and no statistically significant differences were found among all studied populations, with the exception of a Chinese population from Beijing (Po0.001).
Discussion
Apoptosis plays an essential role in homeostasis of the cells. One of the major apoptotic pathways is the receptor-mediated pathway in which FAS plays a central part. FAS is a well-known transmembrane protein which belongs to the TNF receptor family.
Several studies were conducted in order to define the influence of FAS polymorphisms in the Fas-mediated apoptotic pathway. A significantly associated risk was found for FAS À670 A/G polymorphism in bladder, 13 cervical cancer, 11, 16, 22 cutaneous malignant melanoma, 12 esophageal and head and neck squamous cell carcinoma, 15, 21 lung and nasopharyngeal cancer. 9, 17, 20 We analyzed the frequency of FAS genotypes in the normal control population. Our results show that our general population has a profile for FAS À670 A/G polymorphism similar to other Caucasian European and non-European populations. Interestingly, we found differences in the genotype frequencies in comparison to what is reported for a Han Chinese population.
No studies have been reported regarding the evaluation of FAS polymorphisms in prostate cancer patients. Our study is the first to analyze a possible association between FAS polymorphisms and prostate cancer.
Our results revealed that FAS À670 A/G polymorphism may influence the prostate cancer development. It has been reported that allele G reduces the transcriptional activity of FAS gene, 23, 24 consequently reducing the expression of Fas protein. It has been suggested that the reduction of Fas membrane receptor would reduce apoptosis and be associated with a malignant potential. 9, 16, 17 However, our results may be in accordance with the recently published studies suggesting the opposite hypothesis. [41] [42] [43] [44] Fas exists as membrane-bound and soluble forms with opposite roles on triggering apoptosis. They derive from the same gene by alternative splicing. Membrane Fas receptors trigger apoptosis whereas, on the other hand soluble Fas (sFas), which lacks transmembrane domain, binds to Fas ligand antagonizing Fas-Fas ligand apoptotic pathway. 45, 46 Jiang et al. 42 have found an elevated expression with a cytoplasmic staining pattern in high-grade prostatic intraepithelial neoplasia and prostatic adenocarcinomas 43, 44 Serum sFas is also elevated in bladder cancer and is associated with poor prognosis 47 and predicts early recurrences in patients with Ta bladder cancer. 48 Another study in bladder cancer suggests that sFas is likely to be produced and released by bladder urothelial cell carcinoma cells and that urine sFas levels could be an independent predictor of the presence and invasiveness of bladder cancer. 49 Other studies have found an association between sFas expression and serum levels in cancer patients of bile duct carcinoma, 50 breast carcinoma, 51, 52 colon carcinoma, 53 gastric carcinoma, 54 gynecological malignancies 55 and melanoma. 56 According to our results and reinforced by the evidence of the sFas's role in apoptosis and its higher levels in various types of cancer, especially prostate cancer, we hypothesized that the reduction of the expression of Fas caused by G allele would reduce sFas expression levels preventing the anti-apoptotic effect of this protein. Future studies are important to evaluate the influence of FAS polymorphism on serum sFas levels, as well as expression in tissue samples of cancer patients.
